Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma

被引:29
作者
Motoi, Fuyuhiko [1 ]
Murakami, Yoshiaki [2 ]
Okada, Ken-ichi [3 ]
Matsumoto, Ippei [4 ]
Uemura, Kenichiro [2 ]
Satoi, Sohei [5 ]
Sho, Masayuki [6 ]
Honda, Goro [7 ]
Fukumoto, Takumi [8 ]
Yanagimoto, Hiroaki [5 ]
Kinoshita, Shoichi [6 ]
Kurata, Masanao [7 ]
Aoki, Shuichi [1 ]
Mizuma, Masamichi [1 ]
Yamaue, Hiroki [3 ]
Unno, Michiaki [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Surg, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan
[2] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Surg, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan
[3] Wakayama Med Univ, Dept Surg 2, 811-1 Kimiidera, Wakayama 6418510, Japan
[4] Kindai Univ, Fac Med, Dept Surg, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan
[5] Kansai Med Univ, Dept Surg, 2-3-1 Shinmachi, Hirakata, Osaka 5731191, Japan
[6] Nara Med Univ, Dept Surg, 840 Shijo Cho, Kashihara, Nara 6348522, Japan
[7] Tokyo Metropolitan Canc & Infect Dis Ctr, Komagome Hosp, Dept Surg, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan
[8] Kobe Univ, Div Hepatobiliary Pancreat Surg, Dept Surg, Grad Sch Med,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan
基金
日本学术振兴会;
关键词
NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMORADIATION; CA19-9; LEVELS; CANCER; SURVIVAL; GEMCITABINE; CA-19-9; THERAPY; IMPACT; MARGIN;
D O I
10.1007/s00268-018-4814-4
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundSurvival after surgery for pancreatic adenocarcinoma (PA) is poor and heterogeneous, even for curative (R0) resection. Serum carbohydrate antigen (CA) 19-9 levels are important prognostic markers for resected PA. However, sustained elevation of CA19-9 in association with the patterns of recurrence has been rarely investigated.MethodsPatients who underwent R0 resection (n=539) were grouped according to postoperative serum CA19-9 levels (Group E: sustained elevation; Group N: no elevation). Clinicopathological factors, patterns of recurrence, and survival were compared between the groups.ResultsGroup E (n=159) had significantly shorter median overall survival (17.1 vs. 35.4months, p<0.0001) than Group N (n=380). Postoperative CA19-9 elevation was a significant independent predictor of poor survival in multivariate analysis (hazard ratio 1.98, p<0.0001). The rate of hepatic recurrence in Group E was 2.6-fold higher than in Group N (45% vs. 17%, p<0.0001). Postoperative CA19-9 elevation was a strongest independent predictor of primary hepatic recurrence (p<0.0001) by a multiple regression model. Loco-regional, peritoneal, and other distant recurrence did not differ between the groups. The extent of preoperative CA19-9 elevation was correlated sustained elevation of CA19-9 after surgery (p<0.0001) and primary hepatic recurrence (p=0.0019).ConclusionsSustained CA19-9 elevation was strong predictor of primary hepatic recurrence and short survival in cases of R0 resection for PA.
引用
收藏
页码:634 / 641
页数:8
相关论文
共 27 条
[1]   Failure of Normalization of CA19-9 Following Resection for Pancreatic Cancer is Tantamount to Metastatic Disease [J].
Abdel-Misih, Sherif R. Z. ;
Hatzaras, Ioannis ;
Schmidt, Carl ;
Saab, Tanios-Bekaii ;
Klemanski, Dori ;
Muscarella, Peter ;
Melvin, W. Scott ;
Ellison, E. Christopher ;
Bloomston, Mark .
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (04) :1116-1121
[2]   Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma [J].
Barton, Joshua G. ;
Bois, John P. ;
Sarr, Michael G. ;
Wood, Christina M. ;
Qin, Rui ;
Thomsen, Kristine M. ;
Kendrick, Michael L. ;
Farnell, Michael B. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2009, 13 (11) :2050-2058
[3]   Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704 [J].
Berger, Adam C. ;
Garcia, Miguel, Jr. ;
Hoffman, John P. ;
Regine, William F. ;
Abrams, Ross A. ;
Safran, Howard ;
Konski, Andre ;
Benson, Alan B., III ;
MacDonald, John ;
Willett, Christopher G. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) :5918-5922
[4]   The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM [J].
Edge, Stephen B. ;
Compton, Carolyn C. .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (06) :1471-1474
[5]   Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma [J].
Ferrone, Cristina R. ;
Finkelstein, Dianne M. ;
Thayer, Sarah P. ;
Muzikansky, Alona ;
Fernandez-del Castillo, Carlos ;
Warshaw, Andrew L. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2897-2902
[6]  
Hallemeier Christopher L, 2011, Am J Clin Oncol, V34, P567, DOI 10.1097/COC.0b013e3181f946fc
[7]   Pancreatic Cancer Surgery in the New Millennium Better Prediction of Outcome [J].
Hartwig, Werner ;
Hackert, Thilo ;
Hinz, Ulf ;
Gluth, Alexander ;
Bergmann, Frank ;
Strobel, Oliver ;
Buechler, Markus W. ;
Werner, Jens .
ANNALS OF SURGERY, 2011, 254 (02) :311-319
[8]   Prognostic Impact of Postoperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer [J].
Hata, Shojiro ;
Sakamoto, Yoshihiro ;
Yamamoto, Yusuke ;
Nara, Satoshi ;
Esaki, Minoru ;
Shimada, Kazuaki ;
Kosuge, Tomoo .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (02) :636-641
[9]   Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing Morbidity Results of a Prospective Phase II Trial [J].
Heinrich, Stefan ;
Schaefer, Markus ;
Weber, Achin ;
Hany, Thomas F. ;
Bhure, Ujwal ;
Pestalozzi, Bemhard C. ;
Clavien, Pierre-Alain .
ANNALS OF SURGERY, 2008, 248 (06) :1014-1022
[10]   Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation [J].
Katz, Matthew H. G. ;
Varadhachary, Gauri R. ;
Fleming, Jason B. ;
Wolff, Robert A. ;
Lee, Jeffrey E. ;
Pisters, Peter W. T. ;
Vauthey, Jean-Nicolas ;
Abdalla, Eddie K. ;
Sun, Charlotte C. ;
Wang, Huamin ;
Crane, Christopher H. ;
Lee, Jeffrey H. ;
Tamm, Eric P. ;
Abbruzzese, James L. ;
Evans, Douglas B. .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (07) :1794-1801